lundi 13 juillet 2020


Monday, November 14th 2016 at 11:16am UTC

HAMBURG, Germany–(BUSINESS WIRE)– Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its management will present at the Jefferies 2016
Global Healthcare Conference in London, UK, and at the German Equity
Forum 2016, Frankfurt, Germany.

Jefferies 2016 Global Healthcare Conference in London, UK

Date: Thursday, 17 November 2016, 04.00 pm GMT (05.00 pm CET)

Venue: London, UK

Presenter: Enno Spillner, Chief Financial Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation
will be provided at http://www.evotec.com/.

German Equity Forum 2016 in Frankfurt, Germany

Date: Tuesday, 22 November 2016, 10.00 am CET

Venue: Sheraton Frankfurt Airport Hotel and Conference Center,
Frankfurt, Germany

Presenters: Dr Werner Lanthaler,

Chief Executive Officer of Evotec AG;

Enno Spillner,

Chief Financial Officer of Evotec AG

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with
leading pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic to meet the industry’s
need for innovation and efficiency in drug discovery (EVT Execute). The
Company has established a unique position by assembling top-class
scientific experts and integrating state-of-the-art technologies as well
as substantial experience and expertise in key therapeutic areas
including neuroscience, diabetes and complications of diabetes, pain and
inflammation, oncology and infectious diseases. On this basis, Evotec
has built a broad and deep pipeline of more than 70 partnered product
opportunities at clinical, pre-clinical and discovery stages (EVT
Innovate). Evotec has established multiple long-term discovery alliances
with partners including Bayer, CHDI, Sanofi or UCB and development
partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer’s disease, with Sanofi in the field of diabetes and with
Pfizer in the field of tissue fibrosis. For additional information
please go to www.evotec.com.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates
or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

Language:   English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail:

info@evotec.com

Internet:

www.evotec.com/

ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange

Contacts

Evotec AG
Gabriele Hansen, VP Corporate Communications & Investor
Relations
Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com
or
Werner
Lanthaler
040-56081-242, werner.lanthaler@evotec.com

Source: Evotec AG

Étiquettes : , , , , , , , ,